We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+34.9%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$123M
AUM Growth
+$21.1M
(+21%)
Cap. Flow
+$8.21M
Cap. Flow
% of AUM
6.67%
Top 10 Holdings %
Top 10 Hldgs %
62.1%
Holding
78
New
19
Increased
23
Reduced
16
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verastem
VSTM
|
+$9.75M |
| 2 |
Evolus
EOLS
|
+$4.83M |
| 3 |
OmniAb
OABI
|
+$3.92M |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$2.72M |
| 5 |
Abeona Therapeutics
ABEO
|
+$2.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Indivior Pharmaceuticals
INDV
|
+$5.23M |
| 2 |
ITOS
iTeos Therapeutics
ITOS
|
+$3.09M |
| 3 |
ANI Pharmaceuticals
ANIP
|
+$2.52M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$2.39M |
| 5 |
Anika Therapeutics
ANIK
|
+$2.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pulmonx
LUNG
$68M
| $1.09M | 0.88% |
670,000
+524,100
| +359% | +$1.1M |
|
|
DVAX
27
DELISTED
Dynavax Technologies
DVAX
| $1.07M | 0.87% |
108,094
+78,094
| +260% | +$813K |
|
28
Heron Therapeutics
HRTX
$94.1M
| $1.07M | 0.87% |
850,100
+192,720
| +29% | +$306K |
|
29
Vanda Pharmaceuticals
VNDA
$312M
| $973K | 0.79% |
195,000
-55,000
| -22% | -$255K |
|
30
Vir Biotechnology
VIR
$1.5B
| $914K | 0.74% |
160,000
+30,000
| +23% | +$153K |
|
31
MannKind Corp
MNKD
$1.27B
| $846K | 0.69% |
+157,569
| New | +$691K |
|
32
MaxCyte
MXCT
$112M
| $725K | 0.59% |
+459,018
| New | +$798K |
|
33
AN2 Therapeutics
ANTX
$192M
| $716K | 0.58% |
563,913
+19,419
| +4% | +$22.2K |
|
34
Zentalis Pharmaceuticals
ZNTL
$350M
| $685K | 0.56% |
453,800
+344,790
| +316% | +$517K |
|
35
AngioDynamics
ANGO
$610M
| $670K | 0.54% |
60,000
-17,141
| -22% | -$165K |
|
|
GRCE
36
Grace Therapeutics
GRCE
$33.7M
| $628K | 0.51% |
211,010
-81,490
| -28% | -$255K |
|
37
Ultragenyx Pharmaceutical
RARE
$2.56B
| $602K | 0.49% |
+20,000
| New | +$600K |
|
38
Syndax Pharmaceuticals
SNDX
$1.73B
| $572K | 0.47% |
37,200
-55,700
| -60% | -$729K |
|
39
Aquestive Therapeutics
AQST
$467M
| $562K | 0.46% |
+100,600
| New | +$435K |
|
40
Gossamer Bio
GOSS
$87.2M
| $539K | 0.44% |
+204,770
| New | +$451K |
|
|
BOLD
41
Boundless Bio
BOLD
$56.2M
| $509K | 0.41% |
413,453
+307,278
| +289% | +$355K |
|
42
Health Catalyst
HCAT
$154M
| $443K | 0.36% |
155,551
+55,551
| +56% | +$190K |
|
43
Establishment Labs
ESTA
$2.75B
| $434K | 0.35% |
10,585
+3,585
| +51% | +$146K |
|
44
Pliant Therapeutics
PLRX
$65.6M
| $428K | 0.35% |
+289,237
| New | +$441K |
|
45
CytomX Therapeutics
CTMX
$714M
| $399K | 0.32% |
+125,000
| New | +$282K |
|
46
Kiora Pharmaceuticals
KPRX
$11.3M
| $391K | 0.32% |
140,598
-37,402
| -21% | -$103K |
|
47
Rezolute
RZLT
$470M
| $376K | 0.31% |
40,000
-179,000
| -82% | -$1.19M |
|
48
Aclaris Therapeutics
ACRS
$743M
| $367K | 0.3% |
192,900
-298,400
| -61% | -$520K |
|
49
IN8bio
INAB
$10.4M
| $346K | 0.28% |
159,421
+76,991
| +93% | +$169K |
|
50
Solana Company
HSDT
$99.3M
| $298K | 0.24% |
+20,000
| New | +$183K |
|
Similar funds
ER
FDDB
VM
PF
SCM
CWM
EWM
RA
Stonepine Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Stonepine Capital Management held 78 positions worth $123M, up 21% from $102M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Stonepine Capital Management deployed $8.21M of net new capital in Q3 2025, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was OmniAb: 2,142,857 shares worth $3.43M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Indivior Pharmaceuticals, an estimated $5.23M trimmed.
- Stonepine Capital Management's largest Q3 2025 buy was OmniAb: 2,142,857 shares worth $3.43M.
- Stonepine Capital Management added most to Verastem in Q3 2025, an estimated $9.75M increase.
- Stonepine Capital Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $5.23M.
- Stonepine Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $3.09M.
- Stonepine Capital Management's ten largest holdings make up 62% of its $123M portfolio in Q3 2025.
- Stonepine Capital Management opened 19 new positions and closed 20 in Q3 2025.
- Stonepine Capital Management's portfolio value rose 21% quarter-over-quarter to $123M.
Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.